A recently completed study from the Emory University School of Medicine in Atlanta, Georgia, determined that 25% of patients with non-small cell lung cancer (NSCLC) experienced a negative antibody response after receiving COVID-19 mRNA vaccines. Study lead Professor Rafi Ahmed further emphasized that his team "did not find a correlation with the type of cancer treatment and the magnitude of the antibody response." In addition, further research is required as the Emory University study was small, comprised of 82 patients with NSCLC and 53 heathy volunteers.
To read more about this study click here.
Source mentioned: Valanparambil RM, Carlisle J, Linderman SL, et al. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. JCO; Published online 27 June 2022. DOI: 10.1200/JCO.21.02986
No comments:
Post a Comment